MarketVue® Report
Prurigo Nodularis (PN) (U.S.), 2022

Syndicated market assessment report driven by primary market research

REPORT STORE

Prurigo Nodularis (PN) (U.S.), March 2022

DOWNLOAD SAMPLE REPORT
DOWNLOAD REPORT BROCHURE
The MarketVue®: Prurigo Nodularis (PN) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
 
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
 
Topics covered in this report:
  • Disease overview: Review the disease pathophysiology and potential druggable targets
  • Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
  • Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
  • Unmet needs: Identify opportunities to address treatment or disease management gaps
  • Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
  • Value and access: Gain insights into the drug pricing landscape and payer controls within the disease market or analogous markets
 
Methodology:
Research for the MarketVue®: Prurigo Nodularis (PN) report is supported by 4 qualitative interviews with key opinion leaders, a quantitative survey with 20 U.S. physicians and secondary research.
 
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
 
Key companies mentioned:
  • Galderma
  • Sanofi
  • Menlo Therapeutics / Vyne Therapeutics
  • Trevi Therapeutics
  • Incyte
  • Kiniksa
  • Celldex Therapeutics
 
Key drugs mentioned:
  • Methotrexate
  • Gabapentin
  • Dupilumab (Dupixent)
  • Nemolizumab (Nemluvio)
  • Nalbuphine HCl (Haduvio)
  • INCB054707
  • Vixarelimab
  • CDX-0159
  • Serlopitant
  • INCB054707
  • CDX-0159
1. DISEASE OVERVIEW
A rare and chronic inflammatory condition causing itchy nodules on the skin
Figure 1.1 – “Itch-and-scratch” cycle
PN is largely an idiopathic condition
Figure 1.2 – Percentage of PN patients with idiopathic disease
Table 1.1 – Comorbidities associated with PN
Quality of life and psychosocial impact of PN on patients
Figure 1.3 – Percentage of patients experiencing various negative impacts of PN
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1 – G6 diagnosed prevalent cases of PN by region
Table 2.1 – Diagnosed prevalent and drug-treated populations of PN in the U.S. and EU5
PN diagnosis and drug-treatment rates are exceptionally high
Figure 2.2 – Dermatologist-reported segmentation of PN population by disease severity
3. DIAGNOSIS AND CURRENT TREATMENT
Diagnosis overview
Figure 3.1 – Diagnostic journey for PN patients
Lack of FDA-approved treatments for PN
Treatment overview
Table 3.1 – Treatment goals for PN
Figure 3.2 – Dermatologists rating the effectiveness of and satisfaction with current PN therapies
Current treatments for PN
Figure 3.3 – Patient share and physician use of current treatments in PN
Table 3.2 – Upsides and downsides of current treatments used for PN
Current treatments for PN
Figure 3.4 – Percentage of dermatologists who treat PN and their PN patient load
Figure 3.5 – Treatment decision tree for PN
Dermatologists’ opinions on current treatments
Off-label Dupixent use to treat PN
Figure 3.6 – Treatment dynamics of Dupixent use in PN
Key treatment dynamics that shape disease management and drug use in PN
Table 3.3 – Must-know PN treatment dynamics for now and the future
Figure 3.7 – Percentage of PN patients that are eligible for a biologic or advanced systemic
New therapies for PN likely to arrive to the market as label expansions of current therapies
Figure 3.8 – Important dynamics of PN market evolution
4. UNMET NEEDS
Overview
Figure 4.1 – Top unmet needs in PN
Figure 4.2 – Dermatologist-reported unmet needs in PN
Physician perspectives on unmet needs in PN
Figure 4.3 – U.S. dermatologists’ ranking of the need for new treatments in dermatology
5. PIPELINE ANALYSIS
Figure 5.1 – Number of clinical stage therapies addressing unmet needs in PN
Figure 5.2 – Percentage of dermatologists selecting attribute among their top three influencers of treatment selection in PN
Dermatologists are excited about biologics and other mechanisms of action for PN
Table 5.1 – Dermatologists’ rating of how “promising” emerging therapies are on a scale of 1-7
Table 5.2 – Emerging PN therapies, Phase 1 to Phase 3
Dupixent and nemolizumab are out front and poised to compete for first-line biologic use in PN
Figure 5.3 – Differentiation between Dupixent and nemolizumab in PN
Figure 5.4 – Comparison of reduction of itch (WI-NRS) of pipeline agents in moderate-to-severe PN
6. VALUE & ACCESS
Overview
Figure 6.1. Commercial insurance restrictions on Dupixent’s use in atopic dermatitis
Figure 6.2. Dupixent monthly copay payments of Medicare and commercially-insured patients
7. METHODOLOGY
Primary market research approach
Epidemiology methodology
What is the difference between purchasing a published report and requesting a new report?

Published reports have been pre-produced on the specified date and can be delivered immediately. If you prefer to refresh an existing report or request an entirely new disease, REACH can create and deliver any new report within 15 business days.

How does REACH produce new primary market research reports in 15 business days?

By deploying our senior team to each of our reports, we can begin insight generation on day 1. The REACH team also recruits Key Opinion Leaders from our internal panel rather than outsourcing recruitment which enables us to quickly begin primary market research interviews.

Who writes REACH reports?

Each REACH report is produced by one of our senior US-based team members with 10+ years of experience in life sciences market research. We are deeply committed to ensuring REACH reports are high quality and strategic to enable informed decision-making for our clients.

Does REACH cover both rare and non-rare diseases?

REACH specializes in covering diseases and subpopulations that are not addressed by traditional market research reports. As such, we focus on rare diseases and niche subpopulations of more common conditions (e.g., Dupixent-refractory atopic dermatitis). Our flexible model enables in-depth assessments across all disease types, allowing us to support research for non-rare conditions as well.

Can I meet with the team to discuss the report?

Contact us to set up a call directly with the analyst who has written the report to answer any questions and discuss the key takeaways.

Published Report

Download immediately.


New Report

Updated upon purchase. Delivered in 15 days.


Undecided about purchasing this report?

» Inquire before buying

Reach out to learn more about report bundle discounts

Reach out to our team to learn more about our capabilities and view sample reports.

Contact us